High-Density Lipoprotein Particle Subfractions in Heart Failure With Preserved or Reduced Ejection Fraction

被引:46
作者
Hunter, Wynn G. [1 ]
McGarrah, Robert W., III [2 ,3 ]
Kelly, Jacob P. [4 ]
Khouri, Michel G. [2 ]
Craig, Damian M. [3 ]
Haynes, Carol [3 ]
Felker, G. Michael [2 ,5 ]
Hernandez, Adrian F. [2 ,5 ]
Velazquez, Eric J. [2 ,5 ]
Kraus, William E. [2 ,3 ]
Shah, Svati H. [2 ,3 ,5 ]
机构
[1] Duke Univ, Sch Med, Dept Med, Durham, NC 27706 USA
[2] Duke Univ, Sch Med, Dept Med, Div Cardiol, Durham, NC 27706 USA
[3] Duke Mol Physiol Inst, Durham, NC USA
[4] Alaska Heart & Vasc Inst, Anchorage, AK USA
[5] Duke Clin Res Inst, Durham, NC USA
关键词
heart failure; heart failure with preserved ejection fraction; high-density lipoprotein; high-density lipoprotein particles; lipoproteins; HIGH-RISK; CONSENSUS STATEMENT; EUROPEAN-SOCIETY; TASK-FORCE; CHOLESTEROL; HDL; DISEASE; ASSOCIATION; RECLASSIFICATION; SUBCLASSES;
D O I
10.1016/j.jacc.2018.10.059
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND Circulating high-density lipoprotein particle (HDL-P) subfractions impact atherogenesis, inflammation, and endothelial function, all of which are implicated in the pathobiology of heart failure (HF). OBJECTIVES The authors sought to identify key differences in plasma HDL-P subfractions between patients with HF with reduced ejection fraction (HFrEF) and HF with preserved ejection fraction (HFpEF) to determine their prognostic utility. METHODS Patients with HFrEF (n = 782), HFpEF (n = 1,004), and no HF (n + 4,742) were identified in the CATHGEN (Catheterization Genetics) biorepository of sequential patients undergoing cardiac catheterization. Nuclear magnetic resonance-based lipoprotein profiling was performed on frozen fasting plasma obtained at catheterization. The authors used multivariable analysis of covariance to compare high-density lipoprotein particle (HDL-P) subfractions across groups, and Cox proportional hazards modeling to determine associations between HDL-P subfractions and time to death or major adverse cardiac events. RESULTS Mean HDL-P size was greater in HFrEF than HFpEF, both of which were greater than in no HF (all 2-way p < 0.0001). By contrast, concentrations of small HDL-P and total HDL-P were lesser in HFrEF than HFpEF, which were both lesser than no HF (all 2-way p # 0.0002). In both HFrEF and HFpEF, total HDL-P and small HDL-P were inversely associated with time to adverse events. These findings persisted after adjustment for 14 clinical covariates (including high-density lipoprotein cholesterol content, coronary artery disease, and the inflammatory biomarker GlycA), and in sensitivity analyses featuring alternate left ventricular ejection fraction definitions, or stricter inclusion criteria with diastolic dysfunction or left ventricular end-diastolic pressure thresholds. CONCLUSIONS In the largest analysis of HDL-P subfractions in HF to date, derangements in HDL-P subfractions were identified that were more severe in HFrEF than HFpEF and were independently associated with adverse outcomes. These data may help refine risk assessment and provide new insights into the complex interaction of HDL and HF pathophysiology. (J Am Coll Cardiol 2019; 73: 177-86) (c) 2019 Published by Elsevier on behalf of the American College of Cardiology Foundation.
引用
收藏
页码:177 / 186
页数:10
相关论文
共 41 条
[1]   The roles of different pathways in the release of cholesterol from macrophages [J].
Adorni, Maria Pia ;
Zimetti, Francesca ;
Billheimer, Jeffrey T. ;
Wang, Nan ;
Rader, Daniel J. ;
Phillips, Michael C. ;
Rothblat, George H. .
JOURNAL OF LIPID RESEARCH, 2007, 48 (11) :2453-2462
[2]   A Novel Protein Glycan Biomarker and Future Cardiovascular Disease Events [J].
Akinkuolie, Akintunde O. ;
Buring, Julie E. ;
Ridker, Paul M. ;
Mora, Samia .
JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2014, 3 (05)
[3]   High-Density Lipoprotein Particle Subclass Heterogeneity and Incident Coronary Heart Disease [J].
Akinkuolie, Akintunde O. ;
Paynter, Nina P. ;
Padmanabhan, Latha ;
Mora, Samia .
CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES, 2014, 7 (01) :55-63
[4]   Effects of torcetrapib in patients at high risk for coronary events [J].
Barter, Philip J. ;
Caulfield, Mark ;
Eriksson, Mats ;
Grundy, Scott M. ;
Kastelein, John J. P. ;
Komajda, Michel ;
Lopez-Sendon, Jose ;
Mosca, Lori ;
Tardif, Jean-Claude ;
Waters, David D. ;
Shear, Charles L. ;
Revkin, James H. ;
Buhr, Kevin A. ;
Fisher, Marian R. ;
Tall, Alan R. ;
Brewer, Bryan .
NEW ENGLAND JOURNAL OF MEDICINE, 2007, 357 (21) :2109-2122
[5]   Biological activities of HDL subpopulations and their relevance to cardiovascular disease [J].
Camont, Laurent ;
Chapman, M. John ;
Kontush, Anatol .
TRENDS IN MOLECULAR MEDICINE, 2011, 17 (10) :594-603
[6]  
Chakeabarti S, 2010, J CARD FAIL, V16, pS53, DOI 10.1016/j.cardfail.2010.04.004
[7]   High-Density Lipoprotein Particle Size and Concentration and Coronary Risk [J].
El Harchaoui, Karim ;
Arsenault, Benoit J. ;
Franssen, Remco ;
Despres, Jean-Pierre ;
Hovingh, Kees ;
Stroes, Erik S. G. ;
Otvos, James D. ;
Wareham, Nicholas J. ;
Kastelein, John J. P. ;
Khaw, Kay-Tee ;
Boekholdt, S. Matthijs .
ANNALS OF INTERNAL MEDICINE, 2009, 150 (02) :84-U43
[8]   HIGH-DENSITY LIPOPROTEIN AS A PROTECTIVE FACTOR AGAINST CORONARY HEART-DISEASE - FRAMINGHAM STUDY [J].
GORDON, T ;
CASTELLI, WP ;
HJORTLAND, MC ;
KANNEL, WB ;
DAWBER, TR .
AMERICAN JOURNAL OF MEDICINE, 1977, 62 (05) :707-714
[9]   OUTCOME IN MEDICALLY TREATED CORONARY-ARTERY DISEASE - ISCHEMIC EVENTS - NONFATAL INFARCTION AND DEATH [J].
HARRIS, PJ ;
LEE, KL ;
HARRELL, FE ;
BEHAR, VS ;
ROSATI, RA .
CIRCULATION, 1980, 62 (04) :718-726
[10]   HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment [J].
Haynes, Richard ;
Jiang, Lixin ;
Hopewell, Jemma C. ;
Li, Jing ;
Chen, Fang ;
Parish, Sarah ;
Landray, Martin J. ;
Collins, Rory ;
Armitage, Jane .
EUROPEAN HEART JOURNAL, 2013, 34 (17) :1279-1291